what most non-revenue biotech investors dont get is that the market has no interest in IP patents as it perhaps had 15 years ago. Heck, the market does not even care about FDA or MHRA approval, there are many examples of biotech with approved drugs that have seen little increase in market value after approval Outlook Therapeutics Inc comes to mind. Another example is Iovance Biotherapeutics with FDA-approved lifileucel (to treat adult patients with unresectable or metastatic melanoma) in February 2024. Market cap $ 750 million now thats 80% down since FDA approval.
Nowadays, the market ONLY responds to huge non-dilutive cash influxes or, better yet, (rumours of) buyouts. If NWBO has not arranged something in that direction upon UK approval to stop the nonstop dilution, I don't see NWBO's market cap increasing significantly after UK approval.
I know I know what the cult will now be saying. Im a basher because after approval, the market will finally see that NWBO is the Amazon of cancer treatment blabla fantasy blabla, which is the same thing they said that will happen upon arrival of JAMA article, blabla, which is utter BS.
Market Data 
Markets 
AI
